EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin‐1 Pathway

Selin Engür-Öztürk iD, Elif Kaya-Tilki iD, Miriş Dikmen iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Selin Engür-Öztürk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Tavas Vocational School of Health Services, Pamukkale University, Denizli, Turkey. Hauptthemen laut MEDLINE: Aprepitant, Glioblastoma, Substance P, Receptors, Neurokinin-1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anadolu University, Anadolu Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GB) is an aggressive brain tumor characterized by rapid proliferation, invasion, and resistance to therapy. The substance P (SP)/neurokinin‐1 receptor (NK‐1R) pathway contributes to GB progression by promoting angiogenesis, inflammation, and extracellular matrix remodeling. Aprepitant, an FDA‐approved NK‐1R antagonist, has shown potential as a therapeutic agent in glioma treatment.

Methods

This study investigates the anti‐metastatic effects of aprepitant on U87‐MG glioblastoma cells. Cell viability, migration, and invasion were evaluated using WST‐1, real‐time cell analysis, and Oris migration assays. Gene and protein expression levels were assessed by RT‐PCR, ELISA, and microarray analysis.

Results

Aprepitant significantly reduced glioma cell proliferation, migration, and invasion in a dose‐dependent manner. It downregulated pro‐tumorigenic mediators such as VEGF, NF‐kB, TNF‐α, IL‐6, IL‐8, CCL3, CXCL3, and TRIM5, indicating suppression of angiogenesis, inflammation, and chemotaxis pathways.

Discussion

These findings underscore the potent anti‐metastatic and anti‐angiogenic effects of NK‐1R antagonism in glioblastoma and highlight aprepitant as a promising candidate for future in vivo and in ovo therapeutic investigations targeting extracellular matrix (ECM) remodeling, chemotaxis, and angiogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AprepitantGlioblastomaSubstance PReceptors, Neurokinin-1Brain NeoplasmsNeurokinin-1 Receptor AntagonistsAntineoplastic AgentsHumansCell MovementCell Line, TumorSignal TransductionCell ProliferationCell SurvivalGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

NK‐1 receptor antagonistU87‐MGaprepitantsubstance P

Substanzen

AprepitantSubstance PReceptors, Neurokinin-1Neurokinin-1 Receptor AntagonistsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy Services, Tavas Vocational School of Health Services, Pamukkale University, Denizli, Turkey.
  • Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
  • Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.

ORCID-Profile: Selin Engür-Öztürk, Elif Kaya-Tilki, Miriş Dikmen

Förderung

  • Anadolu University
  • Anadolu Üniversitesi

Zitieren

APA

Engür-Öztürk, S., Kaya-Tilki, E., & Dikmen, M. (2025). Anti‐Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin‐1 Pathway. Cancer Medicine. https://doi.org/10.1002/cam4.71148

Vancouver

Engür-Öztürk S, Kaya-Tilki E, Dikmen M. Anti‐Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin‐1 Pathway. Cancer Medicine. 2025. doi:10.1002/cam4.71148

BibTeX
@article{Engrztrk2025,
  author = {Engür-Öztürk, Selin and Kaya-Tilki, Elif and Dikmen, Miriş},
  title = {Anti‐Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin‐1 Pathway},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71148}
}
Kostenlos starten →